131 related articles for article (PubMed ID: 2081384)
1. Sensitivity of the thrombin clotting time and activated partial thromboplastin time to low level of antithrombin III during heparin therapy.
Delorme MA; Inwood MJ; O'Keefe B
Clin Lab Haematol; 1990; 12(4):433-6. PubMed ID: 2081384
[TBL] [Abstract][Full Text] [Related]
2. Monitoring of heparin treatment. Comparison of thrombin time, activated partial thromboplastin time, and plasma heparin concentration, and analysis of the behavior of antithrombin III.
Bounameaux H; Marbet GA; Lämmle B; Eichlisberger R; Duckert F
Am J Clin Pathol; 1980 Jul; 74(1):68-73. PubMed ID: 7395817
[TBL] [Abstract][Full Text] [Related]
3. Multicentric evaluation of heparinase on aPTT, thrombin clotting time and a new PT reagent based on recombinant human tissue factor.
Harenberg J; Reichel T; Malsch R; Hirsh J; Rustagi P
Blood Coagul Fibrinolysis; 1996 Jun; 7(4):453-8. PubMed ID: 8839997
[TBL] [Abstract][Full Text] [Related]
4. [The determination of heparin].
Aiach M
Ann Biol Clin (Paris); 1982; 40(6):645-50. PubMed ID: 7165134
[No Abstract] [Full Text] [Related]
5. [Monitoring heparin therapy by thrombin time and activated partial thromboplastin time--a comparison].
Lang M; Fey MF; Furlan M; Beck EA
Schweiz Med Wochenschr; 1986 Nov; 116(48):1681-4. PubMed ID: 3798064
[TBL] [Abstract][Full Text] [Related]
6. Management of anti-thrombin III deficiency during pregnancy without administration of anti-thrombin III.
Leclerc JR; Geerts W; Panju A; Nguyen P; Hirsh J
Thromb Res; 1986 Feb; 41(4):567-73. PubMed ID: 3961735
[TBL] [Abstract][Full Text] [Related]
7. [Thrombin-antithrombin III complexes as a measure of effective heparin treatment?].
Meyer D; Tsakiris DA; Marbet GA
Schweiz Med Wochenschr; 1989 Sep; 119(39):1352-4. PubMed ID: 2678451
[TBL] [Abstract][Full Text] [Related]
8. Hirudin causes more bleeding than heparin in a rabbit ear bleeding model.
Klement P; Liao P; Hirsh J; Johnston M; Weitz JI
J Lab Clin Med; 1998 Sep; 132(3):181-5. PubMed ID: 9735923
[TBL] [Abstract][Full Text] [Related]
9. Effect of sodium heparin and antithrombin III concentration on activated partial thromboplastin time in the dog.
Hellebrekers LJ; Slappendel RJ; van den Brom WE
Am J Vet Res; 1985 Jul; 46(7):1460-2. PubMed ID: 4026027
[TBL] [Abstract][Full Text] [Related]
10. [Mechanisms of heparin resistance and their clinical significance].
Barkagan ZS; Lychev VG; Bishevskiĭ KM; Tsyvkina LP; Glazunova GA
Ter Arkh; 1982; 54(8):77-82. PubMed ID: 6753220
[No Abstract] [Full Text] [Related]
11. Results of low-dose heparin prophylaxis of venous thrombosis considering plasma heparin and anti-thrombin III concentration.
Tilsner V; Müller U; Reuter H; Raedler A
Thromb Res; 1980 Feb 1-15; 17(3-4):519-25. PubMed ID: 7368173
[No Abstract] [Full Text] [Related]
12. Antithrombin-III plasma activity during and after prolonged use of heparin in unstable angina.
Lidón RM; Théroux P; Robitaille D
Thromb Res; 1993 Oct; 72(1):23-32. PubMed ID: 8122184
[TBL] [Abstract][Full Text] [Related]
13. The influence of heparin, NaCl and CaCl2 on the rate of the thrombin-antithrombin III reaction.
Machovich R; Regoeczi E; Hatton MW
Thromb Res; 1979; 15(5-6):821-34. PubMed ID: 494181
[No Abstract] [Full Text] [Related]
14. The uncalibrated prothrombinase-induced clotting time test. Equally convenient but more precise than the aPTT for monitoring of unfractionated heparin.
Korte W; Jovic R; Hollenstein M; Degiacomi P; Gautschi M; Ferrández A
Hamostaseologie; 2010 Nov; 30(4):212-6. PubMed ID: 21057708
[TBL] [Abstract][Full Text] [Related]
15. Effect of gentamicin on heparin activity.
Tyler LS; Rehder TL; Davis RB
Am J Hosp Pharm; 1981 Apr; 38(4):537-40. PubMed ID: 7282683
[TBL] [Abstract][Full Text] [Related]
16. Clinical evaluation of a new one-stage clotting assay for heparin and low molecular weight heparins.
Harenberg J
J Mal Vasc; 1987; 12 Suppl B():68-70. PubMed ID: 2834495
[TBL] [Abstract][Full Text] [Related]
17. [Perioperative plasma antithrombin activity with "low-dose" heparin prophylaxis. Perioperatively acquired antithrombin III deficiency as a cause for the failure of heparin prophylaxis?].
Kussmann J; Hirche H; Sengupta R
Dtsch Med Wochenschr; 1983 Mar; 108(12):449-52. PubMed ID: 6832015
[TBL] [Abstract][Full Text] [Related]
18. Heparin monitoring by activated partial thromboplastin time. Comparison of ex vivo measurement and in vitro standardization.
Scialla SJ
Am J Clin Pathol; 1985 Sep; 84(3):351-4. PubMed ID: 4036867
[TBL] [Abstract][Full Text] [Related]
19. Evaluation of the activated clotting time and activated partial thromboplastin time for the monitoring of heparin in adult extracorporeal membrane oxygenation patients.
Atallah S; Liebl M; Fitousis K; Bostan F; Masud F
Perfusion; 2014 Sep; 29(5):456-61. PubMed ID: 24570077
[TBL] [Abstract][Full Text] [Related]
20. Respective role of antithrombin III and heparin cofactor II in the in vitro anticoagulant effect of heparin and of various sulphated polysaccharides.
Sie P; Ofosu F; Fernandez F; Buchanan MR; Petitou M; Boneu B
Br J Haematol; 1986 Dec; 64(4):707-14. PubMed ID: 2432917
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
